Answers are grounded in this paper and cite their sources.
Monocytic myeloid-derived suppressor cells (mMDSC) accumulate within tumors where they create an immunosuppressive milieu that inhibits the activity of cytotoxic T and NK cells thereby allowing cancers to evade immune elimination. The TLR7/8 agonist R848 induces human mMDSC to mature into inflammatory macrophage (MACinflam). This work demonstrates that TNFα, IL-6 and IL-10 produced by maturing mMDSC are critical to the generation of MACinflam. Neutralizing either cytokine significantly inhibits R848-dependent mMDSC differentiation. mMDSC cultured in pro-inflammatory cytokine IFNγ or combination of TNFα plus IL-6 differentiate into MACinflam more efficiently than those treated with R848. These mMDSC-derived macrophages exert anti-tumor activity by killing cancer cells. RNAseq analysis of the genes expressed when mMDSC differentiate into MACinflam indicates that TNFα and the transcription factors NF-κB and STAT4 are major hubs regulating this process. These findings support the clinical evaluation of R848, IFNγ and/or TNFα plus IL-6 for intra-tumoral therapy of established cancers.
No takes yet. Share an insight, caveat, or question.
Bayık et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: